BridgeMD
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
EU CTIS ID: 2023-506185-31-00
What this study is testing
To characterize the effect of bexotegrast versus placebo on the change in force vital capacity FVC in participants with idiopathic pulmonary fibrosis (IPF) at Week 52
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. ≥ 40 years of age prior to screening
- 2. IPF diagnosis ≤7 years prior to screening based upon American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Association 2018 guidelines and confirmed with central review (Raghu et al 2018). An HRCT scan performed ≤ 2 years prior to screening may be used for eligibility.
- 3. FVCpp ≥45% confirmed with central review
- 4. Diffusing capacity for carbon monoxide percent predicted (hemoglobin-adjusted) ≥30% and <90% confirmed with central review
- 5. Current treatment for IPF with background therapy is allowed, if at a stable dose for ≥ 12 weeks prior to screening
You likely can't join if
- 1. Receiving pharmacologic therapy for pulmonary hypertension
- 2. Forced expiratory volume in the first second/FVC ratio <0.7 at Screening (as confirmed with central review)
The study team makes the final eligibility decision.
Where it's taking place
- Korea, Democratic People's Republic of
- Australia
- United States
- Brazil
- United Kingdom
- New Zealand
- Turkey
- Israel
- Canada
- China
- Taiwan
- India
- Argentina
- Japan
- Chile
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Korea, Democratic People's Republic of; Australia; United States; Brazil; United Kingdom; New Zealand and 9 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.